{
    "organizations": [],
    "uuid": "285c81cf2ea84571ee7cc35ee0c8d34132fa629b",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-apellis-pharmaceuticals-qtrly-loss/brief-apellis-pharmaceuticals-qtrly-loss-per-share-0-43-idUSASC09YA5",
    "ord_in_thread": 0,
    "title": "BRIEF-Apellis Pharmaceuticals Qtrly Loss Per Share $0.43",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 30 (Reuters) - Apellis Pharmaceuticals Inc:\n* APELLIS PHARMACEUTICALS REPORTS FIRST QUARTER 2018 BUSINESS UPDATE AND FINANCIAL RESULTS\n* APELLIS PHARMACEUTICALS INC QTRLY LOSS PER SHARE $0.43 * APELLIS PHARMACEUTICALS - APL-2 IN GEOGRAPHIC ATROPHY AND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA ON TRACK TO ADVANCE INTO PHASE 3 TRIALS IN 2H18 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-01T04:26:00.000+03:00",
    "crawled": "2018-05-01T19:42:55.002+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "apellis",
        "pharmaceutical",
        "inc",
        "apellis",
        "pharmaceutical",
        "report",
        "first",
        "quarter",
        "business",
        "update",
        "financial",
        "result",
        "apellis",
        "pharmaceutical",
        "inc",
        "qtrly",
        "loss",
        "per",
        "share",
        "apellis",
        "pharmaceutical",
        "geographic",
        "atrophy",
        "paroxysmal",
        "nocturnal",
        "hemoglobinuria",
        "track",
        "advance",
        "phase",
        "trial",
        "2h18",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}